Cardiovascular Effects of YM430,a 1,4-Dihydropyridine Derivative with β-Adrenoceptor Blocking Activity, in Dogs and Rats

スポンサーリンク

概要

• 論文の詳細を見る

• We evaluated the cardiovascular effects of YM430,a novel 1,4-dihydropyridine derivative with β-adrenoceptor blocking activity, in dogs and rats. In anesthetized dogs, YM430 (0.01-0.3 mg/kg, i.v.) dose-dependently decreased mean blood pressure, total peripheral resistance and double product without increasing the heart rate. YM430 (0.01-0.3 mg/kg, i.v.) increased coronary artery as well as vertebral artery blood flow, whereas its effects on carotid, mesenteric, femoral and renal blood flow were small. At the same dose range as that which induced vasodilation effects, YM430 had little effect on the max. dp/dt or PQ-interval. In conscious dogs, YM430 (0.1-1 mg/kg, i.v.) produced dose-dependent hypotension with tachycardia. In conscious rats, oral dosing of YM430 (100 mg/kg p.o.) produced a long-lasting hypotensive effect with slight tachycardia. YM430 also inhibited isoproterenol (0.1 μg/kg i.v.)-induced tachycardia. These two effects of YM430 may be attributable to its calcium entry blocking and β_1-adrenoceptor blocking activity, respectively. The time course of the hypotensive (calcium entry blocking) effect of YM430 after oral dosing was very similar to that of its inhibition of isoproterenol-induced tachycardia (β_1-adrenoceptor blocking effect). These results indicate that the ratio of the two activities (calcium entry blocking and β_1-adrenoceptor blocking) of YM430 is constant after oral administration. In conclusion, YM430 could be both an antianginal and antihypretensive agent, because of its dual activities.

• 公益社団法人日本薬学会の論文
• 1997-03-15

著者

• MASUDA Noriyuki

  Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd.

• UCHIDA Wataru

  Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd.

• Uchida W

  Yamanouchi Pharmaceutical Co. Ltd. Ibaraki Jpn

• Uchida Wataru

  Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co. Ltd.

• Okazaki Toshio

  Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co. Ltd.

• Masuda Noriyuki

  Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co. Ltd.

• Asano M

  Department Of Pharmacology Nagoya City University Medical School

• TAKENAKA Toichi

  Institute for Drug Discovery Research, Yamanouchi Pharmaceutical

• Inagaki Osamu

  Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co.

• Takizawa Kenji

  Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co. Ltd.

• SHIBASAKI Kumiko

  Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd.,

• ASANO Masaharu

  (Present Address)International Clinical Development Department, Yamanouchi Pharmaceutical Co., Ltd.,

• Takenaka T

  Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co. Ltd.

• Takenaka Toichi

  Institute For Drug Discovery Research Yamanouchi Pharmaceutical

• Shibasaki Kumiko

  Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co. Ltd.

関連論文

• Characterization of the Pharmacology of YM-198313 on Volume-Regulated Anion Channels(Pharmacology)
• Cardiac Cysteinyl Leukotriene Receptors and Their Contribution to Coronary Vasoconstriction in Intact Pig Heart(Coronary Circulation, Basic/Clinical 3 (IHD), The 69th Annual Scientific Meeting of the Japanese Circulation Society)
• Increased Expression of Cysteinyl Leukotriene Receptor, CysLT-R2 in Injured Coronary Artery of Pigs(Restenosis after Angioplasty, Basic/Clinical 4 (IHD), The 69th Annual Scientific Meeting of the Japanese Circulation Society)
• Long-term heart rate reduction by zatebradine, an If channel blocker attenuates ventricular remodeling and dysfunction after myocardial infarction in pigs
• FLAVOSTATIN, A NOVEL DISINTEGRIN FROM THE VENOM OF "HABU" (TRIMERESURUS FLAVOVIRIDIS)
• Studies on Cardiac Ingredients of Plants. XIII : Chemical Modification of Gitoxin to Cardiotonic Compounds without Vascular Contractile Effect
• Novel Potassium Channel Activators : Synthesis and Structure-Activity Relationship Studies of 3,4-Dihydro-2H-1,4-benzoxazine Derivatives
• Studies on Nonpeptide Angiotensin II Receptor Antagonists. IV. Synthesis and Biological Evaluation of 4-Acrylamide-1H-imidazole Derivatives
• Studies on Nonpeptide Angiotensin II Receptor Antagonists. III. Synthesis and Biological Evaluation of 5-Alkylidene-3,5-dihydro-4H-imidazol-4-one-Derivatives
• Studies on Nonpeptide Angiotensin II Receptor Antagonists. II. Synthesis and Biological Evaluation of 5H-Pyrazolo[1,5-b][1,2,4]triazole Derivatives with a C-Linked Oxygen Functional Group at the 6-Position
• Studies no Nonpeptide Angiotensin II Receptor Antagonists. I. Synthesis and Biological Evaluation of Pyrazolo[1,5-b][1,2,4]triazole Derivatives with Alkyl Substituents
• Novel Potassium Chennel Activators. II. Synthesis and Pharmacological Evaluation of 3,4-Dihydro-2H-1,4-benzoxazine Derivatives : Modificaiton of the Aromatic Part
• Cardiovascular Effects of YM430,a 1,4-Dihydropyridine Derivative with β-Adrenoceptor Blocking Activity, in Dogs and Rats
• Comparison between YM099 and Captopril in Rats with Renal Mass Reduction-Induced Progressive Renal Disease(Pharmacology)
• Novel Potassium Channel Activators. III. Synthesis and Pharmacological Evaluation of 3,4-Dihydro-2H-1,4-benzoxazine Derivatives : Modification at the 2 Position
• Hypotensive Effects of YM430, a 1 ,4 : Dihydropyridine Derivative, in Spontaneously Hypertensive Rats and Renal Hypertensive Dogs
• Synthesis of Novel Succinamide Derivatives Having the 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one Skeleton as Potent and Selective M_2 Muscarinic Receptor Antagonists. I
• Enhanced Expression of CD69 and CD25 Antigen on Human Peripheral Blood Mononuclear Cells by Prolactin
• Synthesis of Novel Succinamide Derivatives Having a 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one Skeleton as Potent and Selective M_2 Muscarinic Receptor Antagonists. II
• Effects of YM358,an Angiotensin II Type 1 (AT_1) Receptor Antagonist, and Enalapril on Blood Pressure and Vasoconstriction in Two Renal Hypertension Models
• In Vitro and in Vivo Vasodilatory Activity of barnidipine and Its Enantiomers
• Effects of Angiotensin II Type 1 Receptor Antagonist, YM358, on Cardiac Hypertrophy and Dysfunction after Myocardial Infarction in Rats
• Comparison of the Angiotensin II Type 1-Receptor Antagonist YM358 and the Angiotensin-Converting Enzyme Inhibitor Enalapril in Rats With Cardiac Volume Overload
• Antihypertensive Effect of YM730, A New Calcium Antagonist, in Stroke-prone Spontaneously Hypertensive Rats

もっと見る 閉じる

スポンサーリンク